This trial is testing a new cancer drug, BIO-106, as a possible treatment for advanced cancer. This drug will be tested alone and in combination with another cancer drug, pembrolizumab.
- Advanced Solid Tumors
- Advanced Cancer
4 Primary · 6 Secondary · Reporting Duration: 2 years
Side Effects for
Awards & Highlights
2 Treatment Groups
Single agent BIO-106
1 of 2
Combination BIO-106 plus pembrolizumab
1 of 2
332 Total Participants · 2 Treatment Groups
Primary Treatment: BIO-106 · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What goals does this research hope to achieve?
"The primary goal of this long-term study is to document the rate of adverse events and serious adverse events during Phase 1. Additionally, researchers will be looking at anti-tumor activity, defined by objective response rate, disease control rate, duration of response, progression-free survival, and overall survival. These outcomes will also be measured during Phase 2 which is further broken down into an escalation period and expansion period." - Anonymous Online Contributor
Are people still being signed up for this experiment?
"Yes, this study is still recruiting patients. The listing on clinicaltrials.gov shows that it was first posted on March 25th, 2022 and updated as recently as July 15th, 2022." - Anonymous Online Contributor
How many individuals are being given this opportunity to participate in this clinical trial?
"That is correct. According to the information available on clinicaltrials.gov, this research is still looking for patients to enroll. The original posting was March 25th, 2022 and there have been updates as recently as July 15th, 2022. They are currently hoping to enroll 332 individuals from 3 different locations." - Anonymous Online Contributor